• Obtained clinical trial approval of class 1 new drugs XTR003 and XTR004.
• Closed CNY ¥640m series D&D+ financing round co-invested by Hynergy Industrial Funds Management Co., Ltd., Sinopharm Capital, Lotus Lake Captital, Cash Capital and Winning Ventures.